...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Biogen/Eisai Scrap Aducanumab

I would say less than that but still a significant market potential.  THe focus is likely to be on early/vascular dementia.

 

Share
New Message
Please login to post a reply